Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 108INDUSTRY 17OTHER_GOV 7NETWORK 3UNKNOWN 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Carcinoma, Squamous Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Capecitabine 15Paclitaxel 13S 1 (combination) 9apatinib 8Oxaliplatin 8Carboplatin 8Cisplatin 7pyrotinib 6Epirubicin 6Docetaxel 6sintilimab 5camrelizumab 5anlotinib 5Radiotherapy 5Drug Therapy 5130-nm albumin-bound paclitaxel 5nimotuzumab 4nedaplatin 4Vinorelbine 4Temozolomide 4Irinotecan 4Fulvestrant 4Etoposide 4Bevacizumab 4toripalimab 3titanium silicide 3exemestane 3Trastuzumab 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × UNKNOWN × Pemetrexed × Clear all
NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

NCT02829008 2016-07-12

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

ChineseAMS

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡